Association of response endpoints with survival outcomes in multiple myeloma

Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. These improvements have afforded more robust analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Lonial, S, Anderson, K C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918869/
https://www.ncbi.nlm.nih.gov/pubmed/23868105
http://dx.doi.org/10.1038/leu.2013.220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918869/
https://www.ncbi.nlm.nih.gov/pubmed/23868105
http://dx.doi.org/10.1038/leu.2013.220

Ejemplares similares